New treatments for psoriasis: Which biologic is best?

References

• Lundberg L., Johannesson M., Silverdahl M., Hermansson C., Lindberg M. Health‐related quality of life in patients with psoriasis and atopic dermatitis measured with SF‐36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000; 80: 430–4
   PubMed Web of Science ®Google Scholar
• Rapp S. R., Feldman S. R., Exum M. L., Fleischer AB J. r., Reboussin D. M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41((3 Pt 1))401–7
   PubMed Web of Science ®Google Scholar
• Krueger G., Ellis C. N. Psoriasis – recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53((1 suppl 1))S94–100
   Google Scholar
• Mehlis S. L., Gordon K. B. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49((2 suppl))S44–50
   Google Scholar
• Berridge M. J. Lymphocyte activation in health and disease. Crit Rev Immunol 1997; 17: 155–78
   PubMed Web of Science ®Google Scholar
• Schonherr E., Beavan L. A., Hausser H., Kresse H., Culp L. A. Differences in decorin expression by papillary and reticular fibroblasts in vivo and in vitro. Biochem J 1993; 290: 893–9
   PubMed Web of Science ®Google Scholar
• Asadullah K., Docke W. D., Volk H. D., Sterry W. The pathophysiological role of cytokines in psoriasis. Drugs Today (Barc) 1999; 35: 913–24
   PubMed Web of Science ®Google Scholar
• Vollmer S., Menssen A., Trommler P., Schendel D., Prinz J. C. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 1994; 24: 2377–82
   PubMed Web of Science ®Google Scholar
• Feldman S. R., Garton R., Averett W., Balkrishnan R., Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother 2003; 4: 1525–33
   PubMed Web of Science ®Google Scholar
• Tristani‐Firouzi P., Krueger G. G. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998; 61((2 suppl))11–21
   Google Scholar
• Biogen Idec Inc, Amevive (alefacept) package insert; 2005. Cambridge, MA, USA
   Google Scholar
• Genentech Inc, Raptiva (efalizumab) package insert; 2005. South San Fransisco, CA, USA
   Google Scholar
• Immunex Corporation, Enbrel (etanercept) package insert; 2005. Thousand Oaks, CA, USA
   Google Scholar
• Centocor Inc, Remicade (infliximab) package insert; 2005. Malvern, PA, USA
   Google Scholar
• Gottlieb A. B., Evans R., Li S., Dooley L. T., Guzzo C. A., Baker D., et al. Infliximab induction therapy for patients with severe plaque‐type psoriasis: a randomized, double‐blind, placebo‐controlled trial. J Am Acad Dermatol 2004; 51: 534–42
   PubMed Web of Science ®Google Scholar
• Chaudhari U., Romano P., Mulcahy L. D., Dooley L. T., Baker D. G., Gottlieb A. B. Efficacy and safety of infliximab monotherapy for plaque‐type psoriasis: a randomised trial. Lancet 2001; 357: 1842–7
   PubMed Web of Science ®Google Scholar
• Reich K., Nestle F. O., Papp K., Ortonne J. P., Evans R., Guzzo C., et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate‐to‐severe psoriasis: a phase III, multicentre, double‐blind trial. Lancet 2005; 366: 1367–74
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories, Humira (adalimumab) package insert; 2005. Abbott Park, IL, USA
   Google Scholar
• Chen D. M., Gordon K. B., Leonardi C. L., Menter M. A. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12‐week dose‐ranging trial. J Am Acad Dermatol 2004; 50((suppl)(3))1
   Google Scholar
• Leonardi C. L., Powers J. L., Matheson R. T., Goffe B. S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–22
   PubMed Web of Science ®Google Scholar
• Gottlieb A. B., Matheson R. T., Lowe N., Krueger G., Kang S., Goffe B. S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627–32
   PubMed Web of Science ®Google Scholar
• Papp K. A., Tyring S., Lahfa M., Prinz J., Griffiths C. E., Nakanishi A. M., , Etanercept Psoriasis Study Group, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304–12
   PubMed Web of Science ®Google Scholar
• Leonardi C. L., Papp K. A., Gordon K. B., Menter A., Feldman S. R., Caro I., , Efalizumab Study Group, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52((3 Pt 1))425–33
   PubMedGoogle Scholar
• Menter A., Gordon K., Carey W., Hamilton T., Glazer S., Caro I., et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31–8
   PubMed Web of Science ®Google Scholar
• Lebwohl M., Tyring S. K., Hamilton T. K., Toth D., Glazer S., Tawik N. H., et al. A novel targeted T‐cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004–13
   PubMed Web of Science ®Google Scholar
• Gordon K. B., Papp K. A., Hamilton T. K., Walicke P. A., Dummer W., Li N., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073–80
   PubMed Web of Science ®Google Scholar
• Lebwohl M., Christophers E., Langley R., Ortonne J. P., Roberts J., Griffiths C. E. An international, randomized, double‐blind, placebo‐controlled Phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719–27
   PubMed Web of Science ®Google Scholar
• Ortonne J. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17((suppl 2))12–16
   PubMed Web of Science ®Google Scholar
• Finlay A. Y. Psoriasis from the patient's point of view. Arch Dermatol 2001; 137: 352–3
   Google Scholar
• Finlay A. Y., Coles E. C. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236–44
   PubMed Web of Science ®Google Scholar
• Leary M. R., Rapp S. R., Herbst K. C., Exum M. L., Feldman S. R. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. Health Psychol 1998; 17: 530–6
   PubMed Web of Science ®Google Scholar
• Finlay A. Y., Khan G. K. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–16
   PubMed Web of Science ®Google Scholar
• Shikiar R., Bresnahan B. W., Stone S. P., Thompson C., Koo J., Revicki D. A. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53
   PubMedGoogle Scholar
• Mazzotti E., Picardi A., Sampogna F., Sera F., Pasquini P., Abeni D. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003; 149: 318–22
   PubMed Web of Science ®Google Scholar
• Khilji F. A., Gonzalez M., Finlay A. Y. Clinical meaning of change in dermatology life quality index scores. Br J Dermatol 2002; 147((suppl 62))50
   Google Scholar
• Krueger G. G., Langley R. G., Finlay A. Y., Griffiths C. E., Woolley J. M., Lalla D., et al. Patient‐reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005; 153: 1192–9
   PubMed Web of Science ®Google Scholar
• Feldman S. R., Gordon K. B., Bala M., Evans R., Li S., Dooley L. T., et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double‐blind placebo‐controlled trial. Br J Dermatol 2005; 152: 954–60
   PubMed Web of Science ®Google Scholar
• Finlay A. Y., Salek M. S., Haney J. Intramuscular alefacept improves health‐related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206: 307–15
   PubMed Web of Science ®Google Scholar
• 2004 Drug topics red book: pharmacy's fundamental reference. Blackwell, Montvale, NJ 2004
   Google Scholar
• Smith C. H., Anstey A. V., Barker J. N., Burden A. D., Chalmers R. J., Chandler D., , British Association of Dermatologists, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486–97
   PubMed Web of Science ®Google Scholar
• TNF neutralization in MS: results of a randomized., placebo‐controlled multicenter study. 1999: The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999; 53: 457–65
   PubMed Web of Science ®Google Scholar
• Mohan N., Edwards E. T., Cupps T. R., Oliverio P. J., Sandberg G., Crayton H., et al. Demyelination occurring during anti‐tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862–9
   PubMed Web of Science ®Google Scholar